<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Psychopharmacol Neurosci</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin Psychopharmacol Neurosci</journal-id>
      <journal-title-group>
        <journal-title>Clinical Psychopharmacology and Neuroscience</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1738-1088</issn>
      <issn pub-type="epub">2093-4327</issn>
      <publisher>
        <publisher-name>Korean College of Neuropsychopharmacology</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27776398</article-id>
      <article-id pub-id-type="pmc">5083936</article-id>
      <article-id pub-id-type="doi">10.9758/cpn.2016.14.4.405</article-id>
      <article-id pub-id-type="publisher-id">cpn-14-405</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The Relief Effects of Ramelteon on Refractory Chronic Migraine: A Case Report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Hou</surname>
            <given-names>Yi-Cheng</given-names>
          </name>
          <xref ref-type="aff" rid="af1-cpn-14-405">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lai</surname>
            <given-names>Chien-Han</given-names>
          </name>
          <xref ref-type="aff" rid="af2-cpn-14-405">2</xref>
          <xref ref-type="aff" rid="af3-cpn-14-405">3</xref>
          <xref ref-type="corresp" rid="c1-cpn-14-405"/>
        </contrib>
      </contrib-group>
      <aff id="af1-cpn-14-405"><label>1</label>Department of Nutrition, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taipei, 
<country>Taiwan, ROC</country></aff>
      <aff id="af2-cpn-14-405"><label>2</label>Department of Psychiatry, Cheng Hsin General Hospital, Taipei, 
<country>Taiwan, ROC</country></aff>
      <aff id="af3-cpn-14-405"><label>3</label>Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, 
<country>Taiwan, ROC</country></aff>
      <author-notes>
        <corresp id="c1-cpn-14-405">Address for correspondence: Chien-Han Lai, MD, Department of Psychiatry, Cheng Hsin General Hospital, No.45, Cheng Hsin St., Pai-Tou Destrict, Taipei, Taiwan, ROC, Tel: +886-2-28264400 ext 3502, Fax: +886-2-28264570, E-mail: <email>stephenlai99@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <volume>14</volume>
      <issue>4</issue>
      <fpage>405</fpage>
      <lpage>406</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>8</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>24</day>
          <month>3</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2016, Korean College of Neuropsychopharmacology</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access">
          <license-p>This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The selective melatonin receptor agonism effect of ramelteon is useful for insomnia. Here we wanted to present a refractory chronic migraine case, who had significant improvements in migraine after using ramelteon. The possible mechanism for the ramelteon in the migraine relief might be related to melatonin effects.</p>
      </abstract>
      <kwd-group>
        <kwd>Ramelteon</kwd>
        <kwd>Migraine disorders</kwd>
        <kwd>Sleep wake disorders</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The selective melatonin receptor agonism effect of ramelteon is useful for insomnia.<xref rid="b1-cpn-14-405" ref-type="bibr">1)</xref> Here we wanted to present a refractory chronic migraine case, who had significant improvements in migraine after using ramelteon.</p>
    </sec>
    <sec>
      <title>CASE</title>
      <p>A 71 years old female patient suffered from chronic migraine for 2 decades.</p>
      <p>She never had insomnia problems before the first onset of migraine. The migraine occurred 3&#x2013;4 times per week and each episode persisted around 4&#x2013;8 hours. The pulsating pain was localized at right half of the head. The precipitating factors were the stress, increase in physical activities and sudden cold weather. The relieving factors included warm temperature, slower pacing of life and comfortable environment. The moderate or severe pain intensity was aggravated by or causing avoidance of increased physical activity. The residual symptom between the migraine episodes were the head tense feeling, but not achieveing headache severity. The function remained well except avoiding exercise between migraine episodes. No family history of headache was mentioned. The diagnosis was made by the International Headache Society criteria for migraine. The computed tomography revealed no significant findings of other causes for headache, such as tumor or hemorrhage. She ever received many kinds of medications, such as aspirin, nonsteroidal anti-inflammatory drugs, triptans, ergots, anticonvulsants and glucocorticoids. However, the severity of migraine still remained moderate (Migraine Disability Assessment Test [MIDAS] scores, 19) and the associated symptoms were moderate headache, dizziness, nausea, and sensitivity to sound. The migraine also exacerbated her insomnia problems, with fragmented sleep and inadequate sleep duration as 1&#x2013;2 hours (Insomnia Severity Index [ISI] score, 23). She didn&#x2019;t have any comorbid mental disorder except insomnia. Due to the fear of abuse potential related to hypnotics, she chose to receive ramelteon to relieve insomnia. The concurrent analgesic medicine for migraine was ibuprofen 400 mg/day. After 2 weeks treatment of ramelteon 8 mg/day, her sleep duration prolonged to 4&#x2013;5 hours with less fragmentation. In addition, her migraine severity started to decline (MIDAS scores, 11). After 6 months of ramelteon 8 mg/day treatment, the migraine severity continued to relieve (MIDAS scores, 6) with stable sleeping quality (ISI score, 14).</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>In this case, we found significant improvements in migraine severity and insomnia after the use of ramelteon. Since the patient didn&#x2019;t have insomnia before the first onset of migraine. Therefore we could speculate that the ramelteon had significant effects in migraine in such mild prolongation of sleep duration. The melatonin might relieve the headache via the following possible mechanisms, such as anti-inflammatory effect, free radical scavenging, reduction of pro-inflammatory cytokine, membrane stabilization, nitric oxide synthase activity and dopamine release inhibition, GABA and opioid analgesia potentitation, glutamate neurotoxicity protection, neurovascular regulation,<xref rid="b2-cpn-14-405" ref-type="bibr">2)</xref> cytoprotection and antiallodynic action.<xref rid="b3-cpn-14-405" ref-type="bibr">3)</xref> The pineal gland, the primary source of serotonin and melatonin, might also play a significant role in the analgesic effect.<xref rid="b4-cpn-14-405" ref-type="bibr">4)</xref> However, the clinical trial of melatonin administration showed no significant improvements in migraine severity,<xref rid="b5-cpn-14-405" ref-type="bibr">5)</xref> which suggested the modulation of melatonin receptor might be a better option for the analgesic effects. The modulation of serotonin system by the ramelteon would also relieve the pain sensation.<xref rid="b2-cpn-14-405" ref-type="bibr">2)</xref> In addition, the chemical structure of ramelteon was similar with that of indomethacin, which is a kind of non-steroidal anti-inflammatory medicine.<xref rid="b2-cpn-14-405" ref-type="bibr">2)</xref> In the study of animal model, the antinociceptive and antiallodynic actions of melatonin have been observed in different kinds of pathways, such as intrathecally or intracerebroventricular routes. The use of ramelteon, a kind of MT1 and MT2 agonist, could also relieve the pain even lack of free radical scavenger effects.<xref rid="b3-cpn-14-405" ref-type="bibr">3)</xref> The state-of-art treatment of refractory chronic migraine also includes the ramelteon due to selective M1 receptor agonism.<xref rid="b6-cpn-14-405" ref-type="bibr">6)</xref> From the successful experience in this case, we can consider the use of ramelteon for refractory chronic migraine with insomnia.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="b1-cpn-14-405">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reynoldson</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>E</given-names>
              <suffix>Sr</suffix>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Ramelteon: a novel approach in the treatment of insomnia</article-title>
          <source>Ann Pharmacother</source>
          <year>2008</year>
          <volume>42</volume>
          <fpage>1262</fpage>
          <lpage>1271</lpage>
          <pub-id pub-id-type="doi">10.1345/aph.1K676</pub-id>
          <pub-id pub-id-type="pmid">18648020</pub-id>
        </element-citation>
      </ref>
      <ref id="b2-cpn-14-405">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peres</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Masruha</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Zukerman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Moreira-Filho</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Cavalheiro</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Potential therapeutic use of melatonin in migraine and other headache disorders</article-title>
          <source>Expert Opin Investig Drugs</source>
          <year>2006</year>
          <volume>15</volume>
          <fpage>367</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="doi">10.1517/13543784.15.4.367</pub-id>
          <pub-id pub-id-type="pmid">16548786</pub-id>
        </element-citation>
      </ref>
      <ref id="b3-cpn-14-405">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Srinivasan</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pandi-Perumal</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Spence</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Moscovitch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Trakht</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>GM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Potential use of melatonergic drugs in analgesia: mechanisms of action</article-title>
          <source>Brain Res Bull</source>
          <year>2010</year>
          <volume>81</volume>
          <fpage>362</fpage>
          <lpage>371</lpage>
          <pub-id pub-id-type="doi">10.1016/j.brainresbull.2009.12.001</pub-id>
          <pub-id pub-id-type="pmid">20005925</pub-id>
        </element-citation>
      </ref>
      <ref id="b4-cpn-14-405">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toglia</surname>
              <given-names>JU</given-names>
            </name>
          </person-group>
          <article-title>Melatonin: a significant contributor to the pathogenesis of migraine</article-title>
          <source>Med Hypotheses</source>
          <year>2001</year>
          <volume>57</volume>
          <fpage>432</fpage>
          <lpage>434</lpage>
          <pub-id pub-id-type="doi">10.1054/mehy.2001.1337</pub-id>
          <pub-id pub-id-type="pmid">11601864</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-cpn-14-405">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alstadhaug</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Odeh</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Salvesen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bekkelund</surname>
              <given-names>SI</given-names>
            </name>
          </person-group>
          <article-title>Prophylaxis of migraine with melatonin: a randomized controlled trial</article-title>
          <source>Neurology</source>
          <year>2010</year>
          <volume>75</volume>
          <fpage>1527</fpage>
          <lpage>1532</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f9618c</pub-id>
          <pub-id pub-id-type="pmid">20975054</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-cpn-14-405">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lionetto</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Negro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Palmisani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gentile</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Del Fiore</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Mercieri</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Emerging treatment for chronic migraine and refractory chronic migraine</article-title>
          <source>Expert Opin Emerg Drugs</source>
          <year>2012</year>
          <volume>17</volume>
          <fpage>393</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="doi">10.1517/14728214.2012.709846</pub-id>
          <pub-id pub-id-type="pmid">22862686</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
